The plasma metabolic clearance of biologically active luteinizing hormone (bioactive LH) was studied using the rat interstitial cell testosterone (RICT) 
Introduction
Reproductive function is maintained physiologically by the intermittent secretion of biologically active gonadotropic hormones. However, to date, the properties of luteinizing hormone (LH)l production and metabolic disposal have been understood almost exclusively in relation to immunoactive hormone (1) (2) (3) (4) (5) (6) (7) .
Although this approach provides important information regarding some aspects of gonadotropin dynamics, further studies have 1. Abbreviations used in this paper: bioactive LH, biologically active luteinizing hormone; HCG, human chorionic gonadotropin; HMG, human menopausal gonadotropin; IRP, International Reference Preparation; LH, luteinizing hormone; MCR, metabolic clearance rate; RICT, rat interstitial cell testosterone. revealed significant discrepancies between immunoactive and bioactive LH release under conditions ofeither health or disease (8) (9) (10) (11) (12) (13) (14) . In large part, these discrepancies reflect the inability of available immunoassays to directly measure the biologically active constituent(s) of LH in plasma.
In order to define the physiological properties ofbiologically active LH secretion and metabolic clearance, we have infused highly purified human LH in hypogonadotropic men. By employing both bolus injections and continuous equilibrium infusions of graded doses of LH, we have been able to mimic a range of physiological LH concentrations under both dynamic and steady-state conditions. Moreover, in each circumstance, we have been able to directly compare the attributes ofthe plasma disposal ofbiologically active and immunoactive LH in the same subjects.
Methods

Patient characteristics
Six men with hypogonadotropic hypogonadism (immunoactive LH < 3 mIU/ml, bioactive LH < 1.6 mIU/ml) participated in the study after provision of written informed consent, which was approved by the Human Investigation Committee of the University of Virginia School of Medicine (exogenous infusions), or the Clinica Medica V of the University ofRome (endogenous peaks). The patient characteristics are shown in Table I . Each individual had normal serum concentrations ofcortisol, thyroxine, and prolactin, and normal hepatic, renal, and hematologic function. No patient had received any form of LH or human chorionic gonadotropin (HCG) for at least 2 mo before participation in the study. The plasma from these samples was later assayed by RICT and RIA, and the corresponding disappearance curves analyzed by one or two compartment models (discussed further below).
Clinical protocols LHpreparation(s)
Continuous equilibrium infusion protocols. Each ofsix men underwent stepped infusions comprising three doses ofpure human LH, which were divided into three phases as follows: Phase 1 began with basal sampling at 15-min intervals for 1 h followed by the bolus injection of 21 Mg LH and the continuous infusion of 3.5 Mg LH/h for 4 h (four volunteers) or 6 h (two volunteers). The infusion was then stopped for 3 h, until phase 2 was initiated by bolus injection of 34 ,g LH, followed by the continuous infusion of 14 Mg LH/h for 4-6 h. This infusion was then stopped for 3 h, before initiating phase 3, which comprised an 84-pg LH bolus injection followed by the continuous infusion of 35 Mg LH/h for 4-6 h. These infusion rates were chosen to approximate physiological concentrations ofLH at lower doses and to test for saturability ofclearance mechanisms at higher doses.
LH was dissolved in 0.25% human serum albumin/isotonic saline in a volume of 250 ml, which was sterilized by Millipore filtration (Waters Associates, Millipore Corp., Milford, MA). After bolus injections of a loading dose ofLH, continuous infusions were maintained by peristaltic pump at a rate of 40 or 60 ml/h. Blood was sampled at 20-min intervals for the 4 or 6 h of each infusion phase to document attainment of equilibrium plasma LH concentrations. The exact quantities of LH infused were determined by bioassay and immunoassay ofaliquots taken hourly from the actual infusion bottles.
Assays ofLH. Plasma samples were assayed for immunoactive LH by double antibody RIA (1 1, 12) , with a sensitivity of 1 mIU/ml in terms of the Second IRP of HMG, and for bioactive LH by the rat interstitial cell testosterone assay (RICT), with a sensitivity of 0.4 mIU/ml (8, 12) .
The RICT within-assay coefficient of variation averaged 8.5%, with a range from 8.2% in normal men to 9.2% in children and postmenopausal women (1 1, 14) . For the RIA, the coefficients of variation were 8.4% (at 2 mIU/ml), 6.8% (at 11.5 mIU/ml), and 4.6% (at 47 mIU/ml) using LH antiserum that exhibits <15% crossreactivity with alpha subunit (11, 14) . The LH contents of plasma and infusate samples from any single study session were all quantitated in the same assay.
Data analysis. The LH disappearance profiles were analyzed by assuming single or two-component exponential models, such that the in- ( 15) .
Comparisons between bioactive and immunoactive LH values were analyzed by within-subject comparisons using Student's paired two-tailed t test or the Mann-Whitney test in the case of bio/immuno ratios ( 16) . Analysis of variance with correction for repeated measures was used to assess changes in relation to the three stages of the infusions (16). Significance was assumed for P < 0.05.
Results
Bolus injection ofpure human LH. Four men (subjects A-D in Table I 1 ). Peak measured plasma LH concentrations were significantly higher for bioactive LH (275±19 mIU/ml) than immunoactive LH (72±5 mIU/ml) (P < 0.01). However, in both cases, LH concentrations exhibited an initially rapid decline over 1-2 h followed by more delayed disappearance over 3-6 h.
As further illustrated in the lower panel of Fig. 1 , the plasma bio/immuno LH ratio increased from a mean of 1.2±0.4 (median 0.9) basally to a mean of 3.8±0.2 (median 3.8) within 5 min of bolus LH injection (P < 0.001). The bio/immuno LH ratio then gradually increased further to a peak mean value of 5.6±0.4 (median 5.3) at 60 min after the bolus administration of LH (P < 0.05 vs. 5-min value). This value is similar to that reported for endogenous LH peaks (5.27±1.60) (12) . During the remaining portion of the disappearance curves, the bio/immuno ratio was stable at a mean value of 4.64±0.3 (median 4.1), which is not significantly different from the mean value observed in normal men between pulses (12).
The disappearance curves for plasma concentrations of bioactive and immunoactive LH were analyzed by one-and two-component exponential equations. When the disappearance curves were analyzed by single-component exponential decay, the calculated peak amplitudes AO for plasma concentrations of bioactive and immunoactive LH differed significantly (340±94 vs. 66±6) (P = 0.05), as did the alpha (rate-constant) components which corresponded to estimated half-lives of disappearance of 65.3±4.9 min for bioactive LH vs. 46.7±6.8 min for immunoactive LH (P < 0.01). When analyzed by two-component fitting (summarized in Table II ), the calculated amplitudes of both the large and small exponential components were considerably greater for bioactive LH than for immunoactive LH (P = 0.003 for larger component). Comparison ofthe corresponding apparent half-lives of disappearance of bioactive and immunoactive LH also revealed more rapid immunoactive LH disappearance for the rapid component, although this difference did not attain statistical significance.
The preceding analyses indicated that the disappearance properties for human LH differed between bioactive and immunoactive hormones consistently in the amplitude of the more slowly disappearing component, which averaged sixfold larger for bioactive than immunoactive LH. This difference was considerably greater than could be accounted for by the bio/immuno ratio in the infusate (mean 2.43±0.17 [N = 108 samples]). Thus, we tested whether the initial volumes ofdistribution ofbioactive and immunoactive LH were significantly different. As shown in Table III A, independently of the modeling ofthe disappearance curves, the distribution volumes for immunoactive LH were significantly greater than those for bioactive hormone in the same subjects (P < 0.001).
Based upon the disappearance properties of bioactive and immunoactive LH, the apparent metabolic clearance rates (MCRs) for these two species could be calculated (Table III B) . The mean MCR for bioactive LH was 24.1±2.4 (±SEM) ml/ min compared with 56.4±6 ml/min for immunoactive LH (P < 0.03) in the two-compartment model. These values were not significantly different from the corresponding estimates for a single-compartment model. Accordingly, after bolus injection of LH, the apparent MCR for bioactive hormone is less rapid than that for immunoactive hormone in the same individuals, independently ofthe disappearance model chosen. Nonetheless, the absolute values of the apparent MCR for bioactive and immunoactive LH were highly correlated (R = +0.977, P < 0.01).
Continuous graded infusions of LH. In six subjects (A-F, Table I ), pure human LH was administered by bolus injection followed by continuous infusion over three dose ranges. This steady-state technique serves to eliminate possible influences of discrepant distribution volumes. Table IV summarizes the mean plasma concentrations of bioactive and immunoactive LH attained during each ofthe three phases ofLH infusion. Four men were infused for 4 h and two men for 6 h, with blood sampled at 20-min intervals during the infusions to obtain accurate estimates of mean steady state plasma LH concentrations. The results in the four men infused over 4 h are summarized in Fig.  2 , which clearly indicate the attainment of steady-state plasma concentrations of both bioactive and immunoactive LH during this interval. Note that the mean plasma concentrations of bioactive and immunoactive LH attained during the low-dose infusions (Phase I) were within the physiological range of LH measurements for normal healthy adults (1 1, 12, 14) . The higher infusion doses were used to examine the relationship between MCR and plasma LH concentration and test for saturation of metabolic clearance processes (as discussed further below). Fig. 3 depicts the individual MCRs for immunoactive and bioactive LH in each subject studied in relationship to the three doses of LH infused continuously (Phases 1-3). For Phase 1 (low-dose) infusion, the mean MCRs for bioactive and immunoactive LH were, respectively, 28.3+3.4 and 37.1±3.5 ml/min (P < 0.02). Notably, at higher doses of infusion, the apparent (Fig. 4 A) Endogenous LH pulses. To evaluate endogenous LH disappearance rates, blood was withdrawn at 4-10-min intervals for 2-3 h, in six healthy men. The half-lives of disappearance were calculated for endogenous bioactive LH peaks, if at least four consecutively decreasing LH concentrations were measured (Fig. 6) . This permitted the identification of 15 endogenous bioactive LH peaks, with a mean single-component half-life of 13.9±4.4 (SD) min and a range of 5.5-43 min. Although this estimate may include some contribution of initial distribution/ equilibration as well as possibly continued secretion, the values encompass the range (5-48 min) we observed for exogenously injected, highly purified human LH in hypogonadotropic men.
Discussion
Available studies ofthe metabolic clearance of human LH from plasma have emphasized that calculated clearance rates, although validated in several ways, provide estimates of only immunoactive LH, rather than biologically active hormone (1-7). This distinction is particularly important, because recent investigations have disclosed significant discordance between measurements ofimmunoactive and biologically active LH under various pathophysiological conditions (8) (9) (10) (11) (12) (13) (14) . Significant disparities have The present studies using the RICT bioassay indicate that previous estimates of LH production rates from immunoassay data alone markedly underestimate the quantity of biologically assayable hormone secreted under physiological conditions. In contrast, our measurements of immunoactive LH clearance in the same subjects are similar to those reported by other investigators using unlabeled hormone, or immuno-precipitation of radiolabeled LH (1-7) . For example, our mean MCR for immunoactive LH of 34.2±3.2 ml/min in men coincides with that of Marshall et al. (21.3±2.6 ml/min [3] ), and that of Pepperell et al. (43.5±8.2 ml/min [6] ). Thus, our contrasting results with the RICT bioassay suggest that immunospecific methods significantly underestimate the quantities of bioassayable LH activity produced in normal man. In addition, various investigators have reported that sensitive and specific bioassays and radioimmunoassays for LH typically detect bio/immuno LH ratios in excess of unity in normal male plasma (8, (10) (11) (12) . This suggests that many available LH immunoassays fail to recognize the majority of biologically assayable hormone present in the circulation. Similar discrepancies also appear in the identification of bioactive and immunoactive LH pulses in normal men, healthy young women, and postmenopausal individuals, since approximately 16% of bioactive LH pulses are detected without any significant increase in blood immunoactive LH concentrations (11, 12, 14) .
In summary, we have utilized a highly specific, sensitive and precise bioassay of LH to appraise the metabolic clearance of LH bioactivity in man. We investigated the plasma disposal of highly purified LH using both nonequilibrium conditions as well as a range ofsteady-state infusions. These combined approaches allowed comparisons of metabolic clearance rates for both immunoactive and bioassayable LH activity in the same individuals. Our results document certain pitfalls in the analysis of immunoactive LH disappearance after bolus injection, while offering quantitative estimates of the metabolic clearance and production rates of biologically active LH. We believe these results provide an important basis for further investigations ofthe plasma disposal of LH bioactivity. Moreover, these also serve to underscore the restricted ability of immunoassay estimates to reflect fully the behavior of bioactive LH in the circulation.
